Italia markets closed

Dow Jones
39.289,15
+119,63(+0,31%)
Nasdaq
18.005,28
+125,98(+0,70%)
Nikkei 225
40.074,69
+443,63(+1,12%)
EUR/USD
1,0749
+0,0007(+0,06%)
Bitcoin EUR
57.632,51
-1.308,88(-2,22%)
CMC Crypto 200
1.335,27
-9,23(-0,69%)

AbbVie Inc. (4AB.DE)

XETRA - XETRA Prezzo differito. Valuta in EUR.

Aggiungi a watchlist

156,06

-3,32

(-2,08%)

Alla chiusura: 05:35PM CEST

Capitalizzazione	275,582B
Beta (mensile su 5 anni)	0,58
Rapporto PE (ttm)	50,02
EPS (ttm)	3,12
Prossima data utili	26 apr 2024
Rendimento e dividendo (futuro)	5,77 (3,62%)
Data ex dividendo	15 lug 2024
Stima target 1A	N/D

Tutte

GlobeNewswire
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00